share_log

RBC Capital Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $3

Benzinga ·  Nov 3, 2023 14:56

RBC Capital analyst Brian Abrahams maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Outperform and lowers the price target from $4 to $3.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment